CAJ | 학술논문

目的：系统评价KA2012 MBL复合提取液的抗肿瘤活性及对P-gp介导的肿瘤多药耐药的克服能力，并初步探讨KA2012 MBL复合提取液的抗肿瘤机制。方法应用SRB法测定KA2012 MBL复合提取液对K562/A、K562/S和HGC-27的细胞毒活性，应用流式细胞术检测KA2012 MBL复合提取液对K562/S细胞的细胞周期阻滞作用、凋亡诱导作用和对其线粒体膜电位的影响作用。结果 KA2012 MBL复合提取液对肿瘤细胞株K562/A、K562/S和HGC-27均具有细胞毒活性，IC50值分别为（1．12±0．15）％（v/v％）、（1．18±0．04）％（v/v％）、（1．21±0．17）％（v/v％），并可有效克服P-gp介导的肿瘤多药耐药。流式细胞术检测结果显示KA2012MBL复合提取液可有效降低K562/S细胞的线粒体膜电位，并可使 K562/S 细胞阻滞在 G0/G1期，从而诱导其凋亡。结论KA2012 MBL复合提取液通过诱导肿瘤细胞凋亡而杀死肿瘤细胞，同时能克服P-gp介导的肿瘤多药耐药。
목적：계통평개KA2012 MBL복합제취액적항종류활성급대P-gp개도적종류다약내약적극복능력，병초보탐토KA2012 MBL복합제취액적항종류궤제。방법응용SRB법측정KA2012 MBL복합제취액대K562/A、K562/S화HGC-27적세포독활성，응용류식세포술검측KA2012 MBL복합제취액대K562/S세포적세포주기조체작용、조망유도작용화대기선립체막전위적영향작용。결과 KA2012 MBL복합제취액대종류세포주K562/A、K562/S화HGC-27균구유세포독활성，IC50치분별위（1．12±0．15）％（v/v％）、（1．18±0．04）％（v/v％）、（1．21±0．17）％（v/v％），병가유효극복P-gp개도적종류다약내약。류식세포술검측결과현시KA2012MBL복합제취액가유효강저K562/S세포적선립체막전위，병가사 K562/S 세포조체재 G0/G1기，종이유도기조망。결론KA2012 MBL복합제취액통과유도종류세포조망이살사종류세포，동시능극복P-gp개도적종류다약내약。
Objective To evaluate the antitumor activity of KA 2012 MBL and the ability to overcome P -gp mediated MDR in vitro.Methods The cytotoxicity of KA2012MBL against K562/A, K562/S and HGC-27 were determined by SRB as-say.FACS analysis was used to detect the cell cycle arrest activity and apoptosis induction activity of KA 2012MBL on K562/S cells and the loss of mitochondria membrane potential (MMP) of K562/S cells caused by KA2012MBL.Results KA2012MBL showed excellent in vitro cytotoxicity against K562/A,K562/S and HGC-27, with IC50 of (1.12 ±0.15)%(v/v%),(1.18 ±0.04)%(v/v%) and (1.21 ±0.17)%(v/v%),respectively.It also shows ability to overcome P -gp mediated MDR.Furthermore, KA2012MBL caused the loss of MMP of K562/S cells and cell cycle arrest at G 0/G1 phase, and induced the apoptosis of K562/S cells.Conclusion KA2012MBL exerts its antitumor activity by apoptosis induction in tumor cells, which indicates KA2012MBL would show very potent in vivo antitumor activity .Furthermore, KA2012MBL could overcome P-gp mediated MDR successfully .